Impact of preemptive therapy for cytomegalovirus on hospitalizations and cost after hematopoietic stem cell transplantation Journal Article
| Authors: | Fang, J.; Su, Y.; Zavras, P. D.; Raval, A. D.; Tang, Y.; Perales, M. A.; Giralt, S.; Stern, A.; Papanicolaou, G. A. |
| Article Title: | Impact of preemptive therapy for cytomegalovirus on hospitalizations and cost after hematopoietic stem cell transplantation |
| Abstract: | Cytomegalovirus (CMV) viremia occurs in 40% to 80% of CMV-seropositive (R+) recipients of allogeneic hematopoietic cell transplantation (HCT). The preemptive therapy (PET) strategy has reduced the risk of CMV end-organ disease (EOD) and associated mortality but may lead to substantial healthcare resource utilization (HCRU) and costs. Real-world data on the economic impact of PET is relevant for the evaluation of alternative strategies for CMV management. We examined the impact of clinically significant CMV treated with PET on inpatient length of stay (LOS), number of readmissions, and associated costs from day 0 through day 180 post-HCT. This was a retrospective study of R+ adults who underwent peripheral blood or marrow allogeneic HCT at Memorial Sloan Kettering Cancer Center between March 2013 and December 2017. Patients were routinely screened for CMV by qPCR and received PET according to institutional standards of care. Data were extracted from electronic medical records and hospital databases. Itemized cost data per patient were obtained from the Vizient database, adjusted to 2017 dollars using inflation indices. Study outcomes included HCRU evaluated by inpatient LOS and inpatient cost in patients who received PET for clinically significant CMV (PET group) compared with those who did not receive PET (no PET group) and the frequency and cost of CMV-related readmissions compared with non CMV-related readmissions. We used generalized linear models to examine the incremental HCRU and costs associated with PET controlling for other potential factors. Of 357 patients, PET was initiated in 208 (58.3%), at a median of 35 days after HCT. By day 180, 23 patients (6.4%) had developed CMV EOD and 3 (.8%) had died of CMV. Compared with the no PET group, the PET group had a longer LOS for HCT admission (P = .0276), longer total LOS by day 180 (P = .0001), a higher number of readmissions (P = .0001), a higher mean inpatient cost for HCT admission ($189,389 versus $151,646; P = .0133), and a higher total inpatient cost ($297,563 versus $205,815; P < .0001). Among PET recipients, CMV-related readmissions were associated with higher mean cost per episode compared with non CMV-related readmissions ($165,455 versus $89,419; P = .005). CMV-related readmissions comprised 40.6% of total all-cause readmissions and incurred 55.9% of total all-cause readmission costs in PET recipients. Our data show that patients treated with currently available PET had greater inpatient HCRU and cost, by day 180 compared with patients who did not receive PET. The cost of CMV-related readmissions accounted for 56% of total readmission cost among PET recipients. Future studies are needed to examine the cost-effectiveness of alternative strategies for CMV management. © 2020 American Society for Transplantation and Cellular Therapy |
| Keywords: | adult; controlled study; aged; middle aged; young adult; methotrexate; polymerase chain reaction; infection; multiple myeloma; cohort analysis; cyclophosphamide; hematopoietic stem cell transplantation; retrospective study; pneumonia; hospital care; electronic medical record; length of stay; hospitalization; acute graft versus host disease; acute leukemia; myeloablative conditioning; myelodysplastic syndrome; nonmyeloablative conditioning; lymphoma; graft versus host reaction; reduced intensity conditioning; hospital readmission; encephalitis; tacrolimus; rapamycin; foscarnet; ganciclovir; cytomegalovirus infection; cytomegalovirus; african american; hospitalization cost; caucasian; thymocyte antibody; hispanic; antiviral therapy; valganciclovir; hematopoietic cell transplantation; asian; retinitis; preemptive therapy; mycophenolate mofetil; readmission; human; male; female; article; brincidofovir; healthcare resource utilization; letermovir; mismatched unrelated donor; inpatient cost |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 26 |
| Issue: | 10 |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-10-01 |
| Start Page: | 1937 |
| End Page: | 1947 |
| Language: | English |
| DOI: | 10.1016/j.bbmt.2020.06.025 |
| PUBMED: | 32640313 |
| PROVIDER: | scopus |
| PMCID: | PMC8248281 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 November 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work